Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci

被引:18
作者
Kaneko, A [1 ]
Sasaki, J
Shimadzu, M
Kanayama, A
Saika, T
Kobayashi, I
机构
[1] Tokai Univ, Sch Med, Dept Oral Surg, Kanagawa 2591193, Japan
[2] Mitsubishi Kagaku Bioclin Labs Inc, Chemotheapy Div, Itabashi Ku, Tokyo 1748555, Japan
[3] Mitsubishi Kagaku Bioclin Labs Inc, Dept Genet, Itabashi Ku, Tokyo 1748555, Japan
关键词
D O I
10.1093/jac/45.6.771
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Laboratory-derived fluoroquinolone-resistant mutants were obtained by serial passage of Streptococcus sanguis and Streptococcus anginosus isolates on agar containing increasing concentrations of old and new fluoroquinolones, ofloxacin and DU-6859a, respectively. Sequencing of an S. sanguis isolate exposed to DU-6859a showed that resistance was associated with two mutations in the quinolone resistance determining region (QRDR) of the gyrA gene (Ser83-->Phe; Glu87-->Lys), and with a mutation in the parC gene (Ser79-->IIe). However, different mutations in the gyrA gene (Ser83-->Tyr) and parC gene (Ser79-->Phe) were found in a S. sanguis isolate exposed to ofloxacin. A fluoroquinolone-resistant isolate, QR-95101, from a dental Infection, had a single mutation in the gyrA gene (Ser83-->Phe) and in the parC gene (Ser79-->Phe). Two fluoroquinolone-resistant mutants, QS-7010Fm and QS-701DUm, were obtained from S. anginosus QS-701, by exposure to ofloxacin and DU-6859a, respectively. These mutants showed a common substitution at codon 83 (Ser-->Phe) in the gyrA gene but had different substitutions at codon 87 (QS-7010Fm, Glu-->Gln; QS-701DUm, Glu-->Lys). They also had different substitutions at codons 79 and 135 in the parC gene (QS-7010Fm, Ser79-->Leu but no change at Glu135; QS-701DUm, Ser79-->IIe and Glu135-->Gln). The resistance levels of the DU-6859a-selected resistant S. sanguis mutant QS-951DUm to DU-6859a, ofloxacin, ciprofloxacin and norfloxacin were higher than those of the ofloxacin-selected resistant mutant QS-9510Fm. However, ampicillin susceptibilities of these mutants were not different from the parental strains. In S. anginosus, the DU-6859a-selected fluoroquinolone-resistant mutant QS-701DUm was resistant to all the fluoroquinolones tested, while the ofloxacin-selected mutant QS-7010Fm was resistant to three fluoroquinolones, but not DU-6859a. The results indicate that different fluoroquinolones select distinct mutations in the QRDR of the gyrA and parC genes in oral streptococci. The gyrA or parC mutation in oral streptococci may determine the levels of fluoroquinolone resistance.
引用
收藏
页码:771 / 775
页数:5
相关论文
共 17 条
[1]   Species belonging to the ''Streptococcus milleri'' group: Antimicrobial susceptibility and comparative prevalence in significant clinical specimens [J].
Bantar, C ;
Canigia, LF ;
Relloso, S ;
Lanza, A ;
Bianchini, H ;
Smayevsky, J .
JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (08) :2020-2022
[2]   INVITRO ACTIVITY OF SPARFLOXACIN COMPARED WITH THOSE OF 5 OTHER QUINOLONES [J].
CANTON, E ;
PEMAN, J ;
JIMENEZ, MT ;
RAMON, MS ;
GOBERNADO, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (03) :558-565
[3]   CIPROFLOXACIN, A QUINOLONE CARBOXYLIC-ACID COMPOUND ACTIVE AGAINST AEROBIC AND ANAEROBIC-BACTERIA [J].
CHIN, NX ;
NEU, HC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 25 (03) :319-326
[4]   Improved antimicrobial activity of DU-6859a, a new fluoroquinolone, against quinolone-resistant Klebsiella pneumoniae and Enterobacter cloacae isolates with alterations in GyrA and ParC proteins [J].
Deguchi, T ;
Yasuda, M ;
Kawamura, T ;
Nakano, M ;
Ozeki, S ;
Kanematsu, E ;
Nishino, Y ;
Kawada, Y .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2544-2546
[5]   ANALYSIS OF GYRA AND GRLA MUTATIONS IN STEPWISE-SELECTED CIPROFLOXACIN-RESISTANT MUTANTS OF STAPHYLOCOCCUS-AUREUS [J].
FERRERO, L ;
CAMERON, B ;
CROUZET, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (07) :1554-1558
[6]   High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA [J].
Janoir, C ;
Zeller, V ;
Kitzis, MD ;
Moreau, NJ ;
Gutmann, L .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (12) :2760-2764
[7]   Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci [J].
Jorgensen, JH ;
Weigel, LM ;
Ferraro, MJ ;
Swenson, JM ;
Tenover, FC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) :329-334
[8]  
KANEKO A, 1994, CHEMOTHERAPY-TOKYO, V42, P94
[9]   CONTRIBUTION OF THE C-8 SUBSTITUENT OF DU-6859A, A NEW POTENT FLUOROQUINOLONE, TO ITS ACTIVITY AGAINST DNA GYRASE MUTANTS OF PSEUDOMONAS-AERUGINOSA [J].
KITAMURA, A ;
HOSHINO, K ;
KIMURA, Y ;
HAYAKAWA, I ;
SATO, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (07) :1467-1471
[10]   NUCLEOTIDE-SEQUENCE OF THE STAPHYLOCOCCUS-AUREUS GYRB-GYRA LOCUS ENCODING THE DNA GYRASE A-PROTEIN AND B-PROTEIN [J].
MARGERRISON, EEC ;
HOPEWELL, R ;
FISHER, LM .
JOURNAL OF BACTERIOLOGY, 1992, 174 (05) :1596-1603